LENZ Strangle Strategy
LENZ (LENZ Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ (LENZ Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $252.4M, a beta of 1.67 versus the broader market, a 52-week range of 6.83-50.4, average daily share volume of 938K, a public-listing history dating back to 2024, approximately 6 full-time employees. These structural characteristics shape how LENZ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.67 indicates LENZ has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. LENZ pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on LENZ?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current LENZ snapshot
As of May 15, 2026, spot at $7.36, ATM IV 121.40%, IV rank 54.90%, expected move 21.23%. The strangle on LENZ below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on LENZ specifically: LENZ IV at 121.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 21.23% (roughly $1.56 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LENZ expiries trade a higher absolute premium for lower per-day decay. Position sizing on LENZ should anchor to the underlying notional of $7.36 per share and to the trader's directional view on LENZ stock.
LENZ strangle setup
The LENZ strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LENZ near $7.36, the first option leg uses a $7.73 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LENZ chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LENZ shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $7.73 | N/A |
| Buy 1 | Put | $6.99 | N/A |
LENZ strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
LENZ strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on LENZ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on LENZ
Strangles on LENZ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LENZ chain.
LENZ thesis for this strangle
The market-implied 1-standard-deviation range for LENZ extends from approximately $5.80 on the downside to $8.92 on the upside. A LENZ long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current LENZ IV rank near 54.90% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on LENZ should anchor more to the directional view and the expected-move geometry. As a Healthcare name, LENZ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LENZ-specific events.
LENZ strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LENZ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LENZ alongside the broader basket even when LENZ-specific fundamentals are unchanged. Always rebuild the position from current LENZ chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on LENZ?
- A strangle on LENZ is the strangle strategy applied to LENZ (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With LENZ stock trading near $7.36, the strikes shown on this page are snapped to the nearest listed LENZ chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LENZ strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the LENZ strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 121.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LENZ strangle?
- The breakeven for the LENZ strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LENZ market-implied 1-standard-deviation expected move is approximately 21.23%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on LENZ?
- Strangles on LENZ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LENZ chain.
- How does current LENZ implied volatility affect this strangle?
- LENZ ATM IV is at 121.40% with IV rank near 54.90%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.